Companion diagnostics (CDx), i.e. in vitro medical devices, and next-generation sequencing (NGS), are both essential to the practice of precision medicine. As new regulations are introduced, pharma companies and manufacturers alike need to ensure their CDx processes are compliant or we could see a deceleration in the flow of new precision therapies in the near future.Read More
We recently had the pleasure of speaking with Danica Rankic, Associate Principal Scientist, MSD to learn more about their process chemistry activities. She touches on the synthesis strategies impacting drug discovery and provides a snapshot of her upcoming talk, taking place December, 2019.Read More
We recently had the pleasure of interviewing Paul-Peter Tak, CEO of Kintai Therapeutics. Tak discusses how Kintai Therapeutics are exploiting the power of big data and machine learning to unravel the interconnected biology of the gut, and explains how the enteric signaling network can be therapeutically targeted.Read More
Biological complexity is not getting any easier to unravel but utilizing the power of computers could make us better at it.Read More
A receptor (drug target) can shift from a single subunit to a multi-structure in the presence of a ligand (drug compound) – a process known as "oligomerization". Now, using photon excitation microscopy, researchers report that they can uncover the various protein receptor oligomers formed in the absence or presence of different drug candidates that bind to them.Read More
Aided by advances in high-throughput technologies, the metabolomics research field has gained significant traction. We spoke with Baljit Ubhi, Ph.D. from SCIEX, about the recent developments in metabolomics, addressing the increasing focus on the microbiome, how it impacts metabolic disease, and the future directions of research, including "precision nutrition".Read More
Megatrends are overarching trends, ones that seed and embrace multiple market and technology developments. These trends already exist in our world today but are going to be even more important in the years to come. Here we highlight three technology megatrends that could be highly significant to our future.Read More
A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.